BioSpace News Archive

Protalix BioTherapeutics, Inc. announced that it will release its financial results for the third quarter 2019 and business update on Thursday, November 7th, 2019.

Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

REGENXBIO Inc. announced that it will host a conference call on Tuesday, November 5, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2019, and recent operational highlights.

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone.

Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced a response to the U.S. Food and Drug Administration update regarding Type III endoleaks with the AFX Endovascular AAA System..

Gelesis announced that the Company will deliver two oral presentations and one poster at ObesityWeek 2019, the annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society in Las Vegas, Nevada, from November 3-7, 2019.

Logibec Inc. announced the acquisition of Knowledge4You Corporation, a Markham, Ontario-based company.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today confirmed that Tauri-Gum™ will be featured in the New Product Showcase at Kosherfest 2019.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from the Company’s first interim analysis of its ongoing NAV3-31 Phase 2B study.